Prelude Capital Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Prelude Capital Management’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2,500	Closed	-$61K	–	2016
2015 Q2	$61K	Buy	+2,500	New	+$59.9K	0.01%	1087
2015 Q1	–	Sell	-1,560	Closed	-$39K	–	2367
2014 Q4	$39K	Buy	1,560 +260	+20%	+$7.63K	0.01%	1414
2014 Q3	$40K	Sell	1,300 -4,600	-78%	-$125K	0.01%	1470
2014 Q2	$153K	Sell	5,900 -1,700	-22%	-$37.8K	0.02%	859
2014 Q1	$178K	Buy	+7,600	New	+$166K	0.02%	776
2013 Q4	–	Sell	-1,550	Closed	-$32K	–	2131
2013 Q3	$32K	Buy	+1,550	New	+$34.5K	0.01%	1100

Other funds holding SGNT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prelude Capital Management's SGNT Position: Q3 2015 in Review

Prelude Capital Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2015, closing a stake of 2,500 shares — an estimated $61K sold.

Prelude Capital Management first reported a position in SGNT in Q3 2013 and held it in 6 quarters. The position peaked at $178K in Q1 2014. 127 funds tracked by Wall St. Rank hold SGNT as of Q3 2015.

Prelude Capital Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2015 after selling out during the quarter.
Prelude Capital Management sold 2,500 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2015, an estimated $61K.
Prelude Capital Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2013 and held it in 6 quarters.
Prelude Capital Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $178K in Q1 2014.
127 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2015.

Based on Prelude Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.